Breaking News on Global Pharmaceutical Technology & Manufacturing

News in brief

Prosonix scales-up UMAX for respiratory drugs

01-Apr-2010

Related topics: Processing equipment, Processing

Prosonix says UMAX is “technology of choice” for respiratory API production after successfully scaling-up the particle engineering tech for multiple compounds in GMP quality facilities.

CEO David Hipkiss told Outsourcing-pharma the firm, which launched UMAX earlier this month , has now made “kg quantities” of a number of respiratory drug actives including fenoterol hydrobromide and fluticasone propionate.

Hipkiss also said that, in collaboration with Swiss contract manufacturing organisation (CMO) Micro-Sphere, Prosonix has used UMAX to produce “a new innovative pharmaceutical inhalation compound,” but could not provide details for reasons of client confidentiality.

He added that this most recent achievement “further de-risks our novel particle engineering approach and proves beyond doubt that UMAX is here to stay.”

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.